Jun 27, 2023
Jennifer Quinn, Head of global pricing and health economics and outcomes research at Debiopharm, emphasizes the importance of reimbursement, not just regulatory approval, for a drug to be available to patients. With patient-centered outcomes research, drug developers can use data for risk-benefit assessment relevant to regulators that reflect how patients consider the risks and whether they will undergo a procedure.
Jennifer explains, "My team really tries to make sure that, when we're thinking about a clinical development program, we make sure we're capturing those value markers throughout from a very early stage. That is so that when someone out-licenses it and becomes our partner, they have the data they need not just to get through regulatory approval but to have the drug reimbursed and made available to patients."
"It's so important that patients have not just the agency in their care, but we understand how treatments are impacting patients -- impacting their lives, impacting how they feel, impacting their activities of daily living. I think that is what patient-centered outcomes research encompasses: patient preference, patient functioning, and patient feeling. If we don't do that, we are not patient-centric in our drug development because we're missing this crucial part. A drug might shrink a tumor this much, or it might give you this many fewer bleeds if you're a hemophilia patient, but what does that mean to the patient? How does that impact them?"
@DebiopharmNews #Debiopharm #DrugDevelopment #Biotech #PatientCare #PatientCenteredOutcomesResearch
